iGEM 2021 — Team USP-EEL-Brazil

[![](https://static.igem.org/mediawiki/2021/8/8b/HQ_page_logo.jpg)](https://2021.igem.org)

# Team:USP-EEL-Brazil/Notebook

![](https://static.igem.org/mediawiki/2021/f/f7/T--USP-EEL-Brazil--TESTE.png)
![](https://static.igem.org/mediawiki/2021/d/d2/T--KCL_UK--USP-EELCollab1.png)

- [HOME](https://2021.igem.org/Team%3AUSP-EEL-Brazil)
- PROJECT
  * [Project Description](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Description)
  * [Contribution](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Contribution)
  * [Medals](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Medals)
- [PARTS](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Parts)
- LAB
  * Wet-Lab
    + [Experiments](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Experiments)
  * Dry-Lab
    + [Model](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Model)
    + [Engineering Success](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Engineering)
- HUMAN CENTERED DESIGN
  * [Human Practices](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Human_Practices)
  * [Implementation](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Implementation)
  * [Education and Communication](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Communication)- [BEYOND SYNTHETIC BIOLOGY](https://2021.igem.org/Team%3AUSP-EEL-Brazil/BeyondSyntheticBiology)
  - TEAM
    * [Our Team](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Team)
    * [Attributions](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Attributions)
    * [SynBio Club](https://2021.igem.org/Team%3AUSP-EEL-Brazil/CBSin)
    * [Collaborations](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Collaborations%20)
    * [Partnership](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Partnership)
    * [Sponsors](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Sponsors)

# Notebook

Document the dates you worked on your project. This should be a detailed account of the work done each day for your project.

### What should this page have?

* Chronological notes of what your team is doing.
* Brief descriptions of daily important events.
* Pictures of your progress.
* Mention who participated in what task.

### Inspiration

You can see what others teams have done to organize their notes:

* [2018 Munich](https://2018.igem.org/Team%3AMunich/Notebook)
* [2019 Georgia State](https://2019.igem.org/Team%3AGeorgia_State/Notebook)
* [2019 Newcastle](https://2019.igem.org/Team%3ANewcastle/Notebook)
* [2020 IISER Pune India](https://2020.igem.org/Team%3AIISER-Pune-India/Notebook)
* [2020 Lund](https://2020.igem.org/Team%3ALund/Notebook)
* [2020 NOVA LxPortugal](https://2020.igem.org/Team%3ANOVA_LxPortugal/Notebook)
* [2020 RDFZ China](https://2020.igem.org/Team%3ARDFZ-China/NoteBook)

[![](https://static.igem.org/mediawiki/2021/8/8b/HQ_page_logo.jpg)](https://2021.igem.org)

# Team:USP-EEL-Brazil/Engineering

![](https://static.igem.org/mediawiki/2021/f/f7/T--USP-EEL-Brazil--TESTE.png)
![](https://static.igem.org/mediawiki/2021/d/d2/T--KCL_UK--USP-EELCollab1.png)

- [HOME](https://2021.igem.org/Team%3AUSP-EEL-Brazil)
- PROJECT
  * [Project Description](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Description)
  * [Contribution](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Contribution)
  * [Medals](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Medals)
- [PARTS](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Parts)
- LAB
  * Wet-Lab
    + [Experiments](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Experiments)
  * Dry-Lab
    + [Model](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Model)
    + [Engineering Success](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Engineering)
- HUMAN CENTERED DESIGN
  * [Human Practices](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Human_Practices)
  * [Implementation](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Implementation)
  * [Education and Communication](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Communication)- [BEYOND SYNTHETIC BIOLOGY](https://2021.igem.org/Team%3AUSP-EEL-Brazil/BeyondSyntheticBiology)
  - TEAM
    * [Our Team](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Team)
    * [Attributions](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Attributions)
    * [SynBio Club](https://2021.igem.org/Team%3AUSP-EEL-Brazil/CBSin)
    * [Collaborations](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Collaborations%20)
    * [Partnership](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Partnership)
    * [Sponsors](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Sponsors)

![](https://static.igem.org/mediawiki/2021/b/ba/T--USP-EEL-Brazil--sucess.png)

![](https://static.igem.org/mediawiki/2021/7/78/T--USP-EEL-Brazil--brainstorm.png)

In the first research, our team decided to focus on a big problem related to our community. At the first moment we gathered different ideas, that vary from, Bioenergy, to therapeutics and then analyzed them according to what we could do in our University, and the impact in our society.

![](https://static.igem.org/mediawiki/2021/d/d1/T--USP-EEL-Brazil--imagine.png)

Came to our mind, the problematic related to ophidic accidents, and all the difficult for the serum production and the access to the treatment. The findings about the high incidence of ophidic accidents in Brazil, mainly caused by the *Bothrops* genus, and also by analyze the venom composition, we realize that focusing on the Phospholipase A2, was the best path to follow on this project, due to its mionecrotic effect and synergy among other enzymes.

![](https://static.igem.org/mediawiki/2021/1/18/T--USP-EEL-Brazil--design.png)

Our design was made with a T7 Promoter, for a constitutive expression and a compatibility with our *E. coli*, just like our (Ribosome Binding Site [BBa K525998](http://parts.igem.org/wiki/index.php?title=Part:BBa_K525998)). For our coding sequence, we have chosen to use a sequence of a Gamma-Phospholipase A2 Inhibitor from *Bothrops jararaca*, which we cutted off the signal peptide sequence and optimized for our chassis. An important fact is that with this inhibitor, is that due to the similarity of the phospholipase A2 from *B. jararaca* and others snake from *Bothrops* genus and also *Crotalus*, have a significant identity, therefore, we can expect that the Inhibitor should work against Phospholipase A2 from other *Bothrops* and some *Crotalus* species due to its high similarity.

At final we’ve chosen a double terminator ([BBa\_B0015](http://parts.igem.org/Part%3ABBa_B0015)), built with a T7 terminator and an *E. coli* one, to ensure the end of transcription.

![](https://static.igem.org/mediawiki/2021/6/61/T--USP-EEL-Brazil--build.png)

At the Modeling, we first predict some models using the [Modeller](https://salilab.org/modeller/) software where a python code was written for model the structure, followed by using the [I-Tasser](https://zhanggroup.org/I-TASSER/) WebServer, which was able to gather the best 10 templates and predict the best model.

![](https://static.igem.org/mediawiki/2021/0/03/T--USP-EEL-Brazil--test.png)

We have validated our model, by evaluating the C-Score and the TM-Score, which showed us good confidence. Also the inhibition modeling we did, shows us that the inhibition increases with the raise of PLI concentration.

![](https://static.igem.org/mediawiki/2021/0/0f/T--USP-EEL-Brazil--learn.png)

By working on structure and inhibition modelling, we learn about sequence alignment, python, model evaluation and scores, and also about enzymatic kinetic modeling.

![](https://static.igem.org/mediawiki/2021/7/7e/T--USP-EEL-Brazil--improve.png)

Building the model by homology modeling using Modeller we reached a good model by using 3 templates found with the support of the [Swiss-Model](https://swissmodel.expasy.org/) web server. However, we decided to use the i-Tasser web server along with LOMETS, to build a better model with the most accurate templates. With the inhibition modelling, we have a perspective to achieve a precise concentration, since now we have the tendency of inhibition that increases with the concentration of the PLI.

![](https://static.igem.org/mediawiki/2021/7/70/T--USP-EEL-Brazil--future.png)

For future projects we expect to have a docking simulation, to see in molecular and structure levels how inhibition with γPLI from *B. jararaca* works. But mainly to improve and support ophidic accident therapeutics.

![](https://static.igem.org/mediawiki/2021/8/84/T--USP-EEL-Brazil--referencesblue.png)

Serino-Silva C, Morais-Zani K, Hikari Toyama M, Toyama DdO, Gaeta HH, Rodrigues CFB, et al. (2018) Purification and characterization of the first γ-phospholipase inhibitor (γPLI) from *Bothrops jararaca* snake serum. PLoS ONE 13(3): e0193105. [https://doi.org/10.1371/journal. pone.0193105](https://doi.org/10.1371/journal.pone.0193105)

Email: symb-lab@usp.br

[![](https://static.igem.org/mediawiki/2021/b/b7/T--USP-EEL-Brazil--usp.png)](https://www5.usp.br/)
[![](https://static.igem.org/mediawiki/2021/1/17/T--USP-EEL-Brazil--eelusp.png)](https://site.eel.usp.br/home-eel-4)
[![](https://static.igem.org/mediawiki/2018/7/7d/T--USP-EEL-Brazil--patrocinador7.jpg)](https://prp.usp.br/)
[![](https://static.igem.org/mediawiki/2018/a/a4/T--USP-EEL-Brazil--patrocinador10.jpg)](https://prp.usp.br/)
[![](https://static.igem.org/mediawiki/2021/0/0b/T--USP-EEL-Brazil--biolinker.png)](https://biolinker.tech/)
[![](https://static.igem.org/mediawiki/2018/1/1e/T--USP-EEL-Brazil--patrocinador5.jpg)](https://www.idtdna.com/)
[![](https://static.igem.org/mediawiki/2018/8/8b/T--USP-EEL-Brazil--labsegato.jpg)](https://www.facebook.com/SyMBL.EEL.USP/)

[![](https://static.igem.org/mediawiki/2021/8/8b/HQ_page_logo.jpg)](https://2021.igem.org)

# Team:USP-EEL-Brazil/Experiments

![](https://static.igem.org/mediawiki/2021/f/f7/T--USP-EEL-Brazil--TESTE.png)
![](https://static.igem.org/mediawiki/2021/d/d2/T--KCL_UK--USP-EELCollab1.png)

- [HOME](https://2021.igem.org/Team%3AUSP-EEL-Brazil)
- PROJECT
  * [Project Description](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Description)
  * [Contribution](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Contribution)
  * [Medals](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Medals)
- [PARTS](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Parts)
- LAB
  * Wet-Lab
    + [Experiments](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Experiments)
  * Dry-Lab
    + [Model](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Model)
    + [Engineering Success](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Engineering)
- HUMAN CENTERED DESIGN
  * [Human Practices](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Human_Practices)
  * [Implementation](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Implementation)
  * [Education and Communication](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Communication)- [BEYOND SYNTHETIC BIOLOGY](https://2021.igem.org/Team%3AUSP-EEL-Brazil/BeyondSyntheticBiology)
  - TEAM
    * [Our Team](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Team)
    * [Attributions](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Attributions)
    * [SynBio Club](https://2021.igem.org/Team%3AUSP-EEL-Brazil/CBSin)
    * [Collaborations](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Collaborations%20)
    * [Partnership](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Partnership)
    * [Sponsors](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Sponsors)

![](https://static.igem.org/mediawiki/2021/0/0f/T--USP-EEL-Brazil--experiments.png)

Due to the pandemic situation, we only had access to the laboratories in September. Moreover, our genetic syntheses did not arrive in time. Thus, we did not have enough time to carry out the experiments of project Honorato. However, we intend to follow up on them in order to publish a scientific paper.

The experiments described on this page represent what we are going to do. They are the result of our research.

![](https://static.igem.org/mediawiki/2021/d/d4/T--USP-EEL-Brazil--cloning.png)

The microorganism chosen for the reproduction of 𝛾PLI, also called chassis, was the bacterium *E. coli*, selected because it is well characterized in the bibliography and presents easy culture control.

The 3A assembly is a technique for recombining two or more Biobricks, it uses restriction enzymes from the prefixes and suffixes of the Biobricks that will be cleaved at these points, and then recombined so that the prefix of one is recombined with the suffix of the other.

The advantage of this technique is that PCR and DNA electrophoresis are not necessary, and it has high success rates compared to conventional techniques.

In order for the bacteria to incorporate the plasmids they need to receive the right chemical signal and perform a thermal shock to the cells, by increasing the temperature, which makes their membranes more permeable to the entry of these molecules due to the pores that are formed by the pressure difference between the outside and inside of the cell.

![](https://static.igem.org/mediawiki/2021/6/6a/T--USP-EEL-Brazil--purification.png)

The most widely used method for protein purification is using chromatography columns. Through characteristics of the protein, such as size, total charge, or affinity, it is possible to separate the enzyme of interest and other products generated in the culture.

The column contains a porous solid with chemical characteristics that match the type of protein to be purified. This is the stationary phase and is held in a buffered solution. In the mobile phase, the protein to be purified is diluted in this buffer, and migrates through the solid, occurring the separation between the protein of interest and other compounds (NELSON; COX, 2018).

![](https://static.igem.org/mediawiki/2021/b/b9/T--USP-EEL-Brazil--assembling.png)

The coding sequence of 𝛾PLI (EU155170.1) was identified through databases, such as NCBI (National Center for Biotechnology Information), KEGG (Kyoto Encyclopedia of Genes and Genomes).

It will be edited using software for signal peptide removal and codon optimization in order to optimize the chances of successful expression. To facilitate purification, a polyhistidine sequence will be added. The edited sequence will be sent to a company specialized in gene synthesis so that it can be used in the project.

For the production of the enzyme of interest a compound (BBa K525998) of a T7 promoter and RBS will be used, aiming at frequency of gene transcription, and for being a Biobrick well characterized by iGEM times.

A double terminator (BBa\_B0015), formed by an *E. coli* terminator (BBa\_B0010) and a T7 (BBa\_B0012), widely used in *E. coli*, will be used to terminate the transcription, due to its synergy and efficiency, where the E. coli terminator also guarantees the end of transcription by the T7 RNA polymerase and *E. coli* polymerase.

Using the 3A Assembly technique, recombination of the gene sequences will be performed to fit them into the iGEM pattern and obtain the desired cassette.

![](https://static.igem.org/mediawiki/2021/0/01/T--USP-EEL-Brazil--transformation.png)

Transformation techniques, such as heat shock, will be employed for insertion of the exogenous DNA into the *E. coli* BL21 chassis organism. To verify plasmid incorporation, the microorganisms will be selected using selective medium with antibiotic, in this way the resistant cells will be the ones that incorporate the 𝛾-PLI production plasmid.

Subsequently, the microorganisms will be selected using plain LB medium with chlorophenicol 30 mg L-1, then colony PCR will be performed and verification of the gene of interest by electrophoresis. The selected colonies will be grown in liquid LB medium for production of the protein of interest, and then go through a centrifugation process, causing the bacteria containing the enzyme to precipitate, forming pellets, which will be frozen at -80 °C.

As a next step, the pellets will be thawed, resuspended in lysis buffer, and the sonication technique will be applied to break the bacterial cell wall. At the end of the procedure, a supernatant containing the enzymes of interest will be collected and purified using an affinity chromatography column. In the last purification step, the samples that present absorbance peaks will be collected, and the presence of the enzyme of interest will be verified by electrophoresis and biochemical tests.

![](https://static.igem.org/mediawiki/2021/2/26/T--USP-EEL-Brazil--measurement.png)

The standard mixture assay contains 200 µL of buffer (10 mM Tris/HCl, 10 mM CaCl2 and 10 0mM NaCl, pH 7.8), 20 µL of 4-nitro-3-octanoyloxy benzoic acid (4N3OBA) as substrate resulting in the final concentration of 0.25 mM, 20 µL of pure water and 20 µL of PLA2 (approximately 20 µg), will be incubated at 37 °C for 40 min. The hydrolysis values will be determined by absorbance at 425 nm at 5min intervals. The inhibitory effect of 𝛾PLI on PLA2 will be measured by changing absorbance following an incubation of PLA2 (20 µg) and 𝛾PLI (20, 10, 5 and 2.5 µg), mixed for 20min at 37 °C. All assays will be done in triplicate, and the absorbance at 405 nm will be measured using a spectrophotometer.

By means of the absorbance the speed of substrate consumption (nmol/min) will be determined. The percentage of inhibition will be defined by linear regression within the range of 20 to 30 min. The substrate consumption rate (degree of slope), shall be calculated using the formula ((VoPLA2-Vo𝛾PLI)/VoPLA2)100. (SERINO-SILVA et al., 2018).

![](https://static.igem.org/mediawiki/2021/9/91/T--USP-EEL-Brazil--expected.png)

We hope, upon successful completion of the project, that our studies can contribute to a research base aimed at the study of fatal case falls and limb loss from ophidic accidents, by making available a protocol on the production of recombinant 𝛾PLI, and assays of its in vitro efficacy for PLA2 inhibition. And, with a low cost of 𝛾PLI production.

As an application proposal, as a request within a medal requirement in the iGEM molds, we propose the distribution of ampoules containing the recombinant inhibitor in ambulances and also first aid stations, aiming at immediate application after the bite, even before identifying the snake.

We also aim to contribute to the beginning of a basic research aiming the production of a future totally recombinant drug (produced by bacteria), so that in the future we can stop using animals, like the horse, for the production of serum.

![](https://static.igem.org/mediawiki/2021/c/c3/T--USP-EEL-Brazil--references_%281%29.png)

CALGAROTTO, Andrana Karla. Caracterização Físoco-Química de uma fosfolipase A2 Isolada do Veneno de Bothrops moojeni. 2008. Dissertação (Mestrado) - Curso de Biologia Funcional e Molecular, Bioquímica, Universidade Estadual de Campinas, Campinas, 2008. Available on: http://repositorio.unicamp.br/bitstream/REPOSIP/314790/1/Calgarotto\_AndranaKarla\_M.pdf. Access on: March 8, 2021.

CONCEIÇÃO SOBRINHO, Juliana. Inibidor de fosfolipase A2 tipo gama da serpente Bothrops atrox (atPLI): estudos on silico e in vitro de peptídeos sintéticos e análise de sistemas de expressão heteróloga do atPLI. 2018. 142f. Tese (Doutorado em Biologia Experimental) - Programa de Programa de Pós-Graduação em Biologia Experimental (PGBIOEXP), Fundação Universidade Federal de Rondônia (UNIR), Porto Velho, 2018.

SERINO-SILVA, Caroline. Purificação e caracterização do primeiro inibidor de fosfolipases A2 do tipo gama presente no soro da serpente Bothrops jararaca. 2017. 62 f. Tese (Doutorado) - Curso de Mestre em Biotecnologia, Universidade de São Paulo, São Paulo, 2017.

SANTOS-FILHO, Norival Alves. Caracterização Funcional e Estrutural de uma
Fosfolipase A2 Ácida Tóxica Isolada da Peçonha de Bothrops moojeni. Universidade de São Paulo Faculdade de Ciências Farmacêuticas de Ribeirão Preto, São Paulo, 2009

MAGALHÃES, A. Regina. Caracterização de enzimas em peçonhas animais: identificação de fosfolipases do escorpião Hadrurus gerstchi e atividades enzimáticas da arraia Potamotrygon falkneri. 2017. 97 f. Tese (Doutorado) - Curso de Mestre em Biotecnologia, Universidade de Brasília, Brasília, 2017.

FERNANDES, Carlos. Estudos estruturais com toxinas de venenos de serpentes. In: FERNANDES, Carlos. Ciências biológicas. São Paulo: Unesp Ciência, 2017. p. 9-15.

COSTA, Kellen Cristina Torres. AVALIAÇÃO DOS EFEITOS SISTÊMICOS INDUZIDOS POR UMA FOSFOLIPASE A2 ISOLADA DA PEÇONHA DA SERPENTE Bothrops moojeni. 2017. 56 f. Tese (Doutorado) - Curso de Mestre em Ciências Biológicas, Universidade Federal de Uberlândia, Uberlândia, 2017.

CASTRO, Isac de. Estudo da toxicidade das peçonhas crotálicas e botrópicas, no acidente ofídico, com ênfase a toxicidade renal. O Mundo da Saúde, São Paulo, v. 30, n. 4, p. 644-653, 5 dez. 2006.

PICELLI, Carina Godoy. Caracterização de fosfolipases A2 da peçonha de Bothrops bilineata e identificação do gene de inibidores de fosfolipases A2 de classe gama em Bothrops atrox e Micrurus lemniscatus: um estudo com ênfase no potencial biotecnológico. 2013, Porto Velho - RO.

ACIDENTES POR ANIMAIS PEÇONHENTOS. Datasus [internet], 2019. Available at: . Access on: September 20, 2021.

(BIBLIOTECA VIRTUAL DE SAÚDE. 19/9- Dia Internacional de Atenção aos Acidentes Ofídicos, c2021. Página inicial. Available at:. Access on: May 21, 2021.

Brasil. Ministério da Saúde. Ofidismo: Análise Epidemiológica. Brasília, 1991.

REGISTRY OF STANDARD BIOLOGICAL PARTS (comp.). Assembly/3A Assembly. Available at: http://parts.igem.org/Help:Assembly/3A\_Assembly. Access on: May 13, 2021

Email: symb-lab@usp.br

[![](https://static.igem.org/mediawiki/2021/b/b7/T--USP-EEL-Brazil--usp.png)](https://www5.usp.br/)
[![](https://static.igem.org/mediawiki/2021/1/17/T--USP-EEL-Brazil--eelusp.png)](https://site.eel.usp.br/home-eel-4)
[![](https://static.igem.org/mediawiki/2018/7/7d/T--USP-EEL-Brazil--patrocinador7.jpg)](https://prp.usp.br/)
[![](https://static.igem.org/mediawiki/2018/a/a4/T--USP-EEL-Brazil--patrocinador10.jpg)](https://prp.usp.br/)
[![](https://static.igem.org/mediawiki/2021/0/0b/T--USP-EEL-Brazil--biolinker.png)](https://biolinker.tech/)
[![](https://static.igem.org/mediawiki/2018/1/1e/T--USP-EEL-Brazil--patrocinador5.jpg)](https://www.idtdna.com/)
[![](https://static.igem.org/mediawiki/2018/8/8b/T--USP-EEL-Brazil--labsegato.jpg)](https://www.facebook.com/SyMBL.EEL.USP/)

[![](https://static.igem.org/mediawiki/2021/8/8b/HQ_page_logo.jpg)](https://2021.igem.org)

# Team:USP-EEL-Brazil/Results

![](https://static.igem.org/mediawiki/2021/f/f7/T--USP-EEL-Brazil--TESTE.png)
![](https://static.igem.org/mediawiki/2021/d/d2/T--KCL_UK--USP-EELCollab1.png)

- [HOME](https://2021.igem.org/Team%3AUSP-EEL-Brazil)
- PROJECT
  * [Project Description](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Description)
  * [Contribution](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Contribution)
  * [Medals](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Medals)
- [PARTS](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Parts)
- LAB
  * Wet-Lab
    + [Experiments](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Experiments)
  * Dry-Lab
    + [Model](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Model)
    + [Engineering Success](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Engineering)
- HUMAN CENTERED DESIGN
  * [Human Practices](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Human_Practices)
  * [Implementation](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Implementation)
  * [Education and Communication](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Communication)- [BEYOND SYNTHETIC BIOLOGY](https://2021.igem.org/Team%3AUSP-EEL-Brazil/BeyondSyntheticBiology)
  - TEAM
    * [Our Team](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Team)
    * [Attributions](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Attributions)
    * [SynBio Club](https://2021.igem.org/Team%3AUSP-EEL-Brazil/CBSin)
    * [Collaborations](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Collaborations%20)
    * [Partnership](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Partnership)
    * [Sponsors](https://2021.igem.org/Team%3AUSP-EEL-Brazil/Sponsors)

# Results

You can describe the results of your project and your future plans here.

### What should this page contain?

* Clearly and objectively describe the results of your work.
* Future plans for the project.
* Considerations for replicating the experiments.

### Describe what your results mean

* Interpretation of the results obtained during your project. Don't just show a plot/figure/graph/other, tell us what you think the data means. This is an important part of your project that the judges will look for.
* Show data, but remember **all measurement and characterization data must also be on the Part's Main Page on the [Registry](http://parts.igem.org/Main_Page).** Otherwise these data will not be in consideration for any medals or part awards!
* Consider including an analysis summary section to discuss what your results mean. Judges like to read what you think your data means, beyond all the data you have acquired during your project.

### Project Achievements

You can also include a list of bullet points (and links) of the successes and failures you have had over your summer. It is a quick reference page for the judges to see what you achieved during your summer.

* A list of linked bullet points of the successful results during your project
* A list of linked bullet points of the unsuccessful results during your project. This is about being scientifically honest. If you worked on an area for a long time with no success, tell us so we know where you put your effort.

### Inspiration

See how other teams presented their results.

* [2019 Newcastle](https://2019.igem.org/Team%3ANewcastle/Results)
* [2019 Munich](https://2019.igem.org/Team%3AMunich/Results)
* [2019 Tec Chihuahua](https://2019.igem.org/Team%3ATec-Chihuahua/Results)
* [2020 Aalto Helsinki](https://2020.igem.org/Team%3AAalto-Helsinki/Results)
* [2020 GreatBay SCIE](https://2020.igem.org/Team%3AGreatBay_SCIE/Results)
* [2020 Queens Canada](https://2020.igem.org/Team%3AQueens_Canada/Results)